19:31 , Sep 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Sarcoma Mouse studies suggest combining DIABLO mimetics with an oncolytic vesicular stomatitis virus (VSV) could help treat rhabdomyosarcoma. In an orthotopic xenograft mouse model of the cancer, the DIABLO mimetic LCL161 plus an oncolytic VSV...
20:34 , Jul 21, 2017 |  BC Week In Review  |  Clinical News

Debiopharm completes enrollment in Phase I/II of Debio 1143 for SCCHN

Debiopharm Group (Lausanne, Switzerland) completed enrollment of 96 patients with previously untreated, locally advanced squamous cell carcinoma of the head and neck (SCCHN) in the Phase II portion of a double-blind, placebo-controlled, French and Swiss...
18:04 , Jul 10, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture studies identified a compound that recruits androgen receptor to IAP for proteasomal degradation that could help treat prostate cancer. The compound consisted of an androgen receptor ligand and a peptidomimetic of...
23:19 , Nov 3, 2016 |  BC Week In Review  |  Company News

TetraLogic, Medivir deal

Medivir will acquire birinapant and suberohydroxamic acid phenyl ester (SHAPE) from TetraLogic for $12 million up front in cash; TetraLogic will subsequently delist from NASDAQ and terminate all remaining employees by Dec. 1. TetraLogic shareholders...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Company News

NBE-Therapeutics, Sotio deal

Sotio and NBE partnered to discover and develop next-generation antibody-drug conjugates (ADCs) against undisclosed targets to treat cancer. The collaboration will use NBE’s Transpo-mAb antibody platform, SMAC conjugation technology and toxin platform. The partners will...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Clinical News

AT-406: Phase II started

Debiopharm began a double-blind Phase II trial of oral Debio 1143 plus carboplatin and paclitaxel. Debiopharm has exclusive, worldwide rights from Ascenta to develop and commercialize Debio 1143 (see BioCentury, Sept. 12, 2011). Ascenta Therapeutics...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

Birinapant: Phase II discontinued

TetraLogic said it will terminate a double-blind, international Phase II trial after an interim analysis of 62 evaluable azacitidine-naive patients with higher risk MDS showed that twice-weekly 13 mg/m 2 IV birinapant for 3 weeks...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Clinical News

Birinapant: Preliminary Phase IIa data

Preliminary data from 9 azacitidine-naive patients with higher risk MDS in a double-blind, placebo-controlled, international Phase IIa trial showed that twice-weekly 13 mg/m 2 IV birinapant for 3 weeks of a 4-week cycle plus azacitidine...
07:00 , May 25, 2015 |  BC Week In Review  |  Clinical News

Birinapant: Phase Ib/IIa halted

TetraLogic temporarily halted enrollment in a double-blind, placebo-controlled, Australian Phase Ib/IIa trial of IV birinapant following observed cranial nerve palsies in 2 of the 7 patients in the first cohort receiving the 1.4 mg/m 2...
07:00 , May 18, 2015 |  BC Week In Review  |  Company News

TetraLogic, Merck deal

TetraLogic and Merck will jointly conduct a Phase I trial evaluating TetraLogic’s birinapant in combination with Merck’s Keytruda pembrolizumab to treat relapsed or refractory solid tumors. TetraLogic will fund the study, and Merck will...